Navigation Links
Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Date:3/30/2009

ropriate access to IPLEX(TM)."

"We are pleased to be working with Insmed in order to expand access to IPLEX(TM), a drug that has shown significant potential in multiple important therapeutic categories," said John Lagus, Vice President of Business Development for IDIS.

About IPLEX(TM)

IPLEX(TM) was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM) rhIGF-I/rhIGFBP-3), is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

About IDIS

IDIS is the world leader in the development and implementation of Named Patient Programs and has a proven track record of working in strategic partnership with U.S.-based companies to bring new medicines to Europe for the first time. IDIS supports its customers in over 100 countries worldwide, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. Headquartered near central London, IDIS has been a strategic partner to more than 40 pharmaceutical and biotech companies. For more information on IDIS, please visit the website www.idispharma.com or contact John Lagus at '/>"/>

SOURCE Insmed Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
2. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
3. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
4. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
5. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
6. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
7. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
8. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
9. Insmed to Seek Shareholder Approval for Reverse Split
10. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
11. Insmed to Present at Biosimilars 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Neogen CEO adopts 10b5-1 Trading Plan 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3
... Based on Company,s, microRNA Technology, Developed by Columbia University Medical Center, ... Approved for Clinical use Acquires CLIA-certified lab to Expedite Commercialization of its ... microRNA-based Tests, Expands Pipeline With Three Additional microRNA-based ... Development, ...
... Calif., Aug. 18 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... and,revises its full year 2008 guidance. The Company ... and certain balance sheet accounts,to record additional expenses ... in prior periods since the adoption of Statement,of ...
... BeaconEquity.com announces the,availability of Trade Alerts on stocks making ... trading notes for free by visiting:, http://www.BeaconEquity.com/m , Today,s ... Pfizer Inc.,(NYSE: PFE ), Amgen Inc. (Nasdaq: AMGN ... BIIB ) and Gilead Sciences Inc. (Nasdaq: GILD ...
Cached Biology Technology:Rosetta Genomics Reports Second Quarter 2008 Financial Results 2Rosetta Genomics Reports Second Quarter 2008 Financial Results 3Rosetta Genomics Reports Second Quarter 2008 Financial Results 4Rosetta Genomics Reports Second Quarter 2008 Financial Results 5Rosetta Genomics Reports Second Quarter 2008 Financial Results 6Rosetta Genomics Reports Second Quarter 2008 Financial Results 7Rosetta Genomics Reports Second Quarter 2008 Financial Results 8Rosetta Genomics Reports Second Quarter 2008 Financial Results 9Rosetta Genomics Reports Second Quarter 2008 Financial Results 10Rosetta Genomics Reports Second Quarter 2008 Financial Results 11Rosetta Genomics Reports Second Quarter 2008 Financial Results 12VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 3VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 4BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD 2BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD 3
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... of cells perform a feat that still amazes researchers with ... other. The process is called mitosis, and an inability to ... Little is known about the biochemical processes that ... and Technion-Israel Institute of Technology in Haifa, Israel, have discovered ...
... be the worst enemy for our waistlines, according to researchers ... They found that study subjects on strict diet and exercise ... they eat more on weekends than during the week. The ... the journal Obesity . Past research had confirmed ...
... recycling more, and going green be easier if ... the question a team of Canadian industry consultants ... in a forthcoming issue of the International ... Inderscience Publishers. The researchers recruited twenty willing ...
Cached Biology News:Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3Weekends slow weight loss, researchers find 2Weekends slow weight loss, researchers find 3Shrinking carbon footprints 2Shrinking carbon footprints 3
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
...
Immulon 1 B 1x12 Strip, flat bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
...
Biology Products: